HIV-associated anemia after 96 weeks on therapy: determinants across age ranges in Uganda and Zimbabwe.
Given the detrimental effects of HIV-associated anemia on morbidity, we determined factors associated with anemia after 96 weeks of antiretroviral therapy (ART) across age groups. An HIV-positive cohort (n=3,580) of children age 5-14, reproductive age adults 18-49, and older adults ≥50 from two rand...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2014
|
| _version_ | 1797085351006699520 |
|---|---|
| author | Jaganath, D Walker, A Ssali, F Musiime, V Kiweewa, F Kityo, C Salata, R Mugyenyi, P |
| author_facet | Jaganath, D Walker, A Ssali, F Musiime, V Kiweewa, F Kityo, C Salata, R Mugyenyi, P |
| author_sort | Jaganath, D |
| collection | OXFORD |
| description | Given the detrimental effects of HIV-associated anemia on morbidity, we determined factors associated with anemia after 96 weeks of antiretroviral therapy (ART) across age groups. An HIV-positive cohort (n=3,580) of children age 5-14, reproductive age adults 18-49, and older adults ≥50 from two randomized trials in Uganda and Zimbabwe were evaluated from initiation of therapy through 96 weeks. We conducted logistic and multinomial regression to evaluate common and differential determinants for anemia at 96 weeks on therapy. Prior to initiation of ART, the prevalence of anemia (age 5-11 <10.5 g/dl, 12-14 <11 g/dl, adult females <11 g/dl, adult males <12 g/dl) was 43%, which decreased to 13% at week 96 (p<0.001). Older adults had a significantly higher likelihood of anemia compared to reproductive age adults (OR 2.60, 95% CI 1.44-4.70, p=0.002). Reproductive age females had a significantly higher odds of anemia compared to men at week 96 (OR 2.56, 95% CI 1.92-3.40, p<0.001), and particularly a greater odds for microcytic anemia compared to males in the same age group (p=0.001). Other common factors associated with anemia included low body mass index (BMI) and microcytosis; greater increases in CD4 count to week 96 were protective. Thus, while ART significantly reduced the prevalence of anemia at 96 weeks, 13% of the population continued to be anemic. Specific groups, such as reproductive age females and older adults, have a greater odds of anemia and may guide clinicians to pursue further evaluation and management. |
| first_indexed | 2024-03-07T02:07:44Z |
| format | Journal article |
| id | oxford-uuid:9f8fe664-d9de-44b9-813d-4eee9a5286a1 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T02:07:44Z |
| publishDate | 2014 |
| record_format | dspace |
| spelling | oxford-uuid:9f8fe664-d9de-44b9-813d-4eee9a5286a12022-03-27T00:58:52ZHIV-associated anemia after 96 weeks on therapy: determinants across age ranges in Uganda and Zimbabwe.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:9f8fe664-d9de-44b9-813d-4eee9a5286a1EnglishSymplectic Elements at Oxford2014Jaganath, DWalker, ASsali, FMusiime, VKiweewa, FKityo, CSalata, RMugyenyi, PGiven the detrimental effects of HIV-associated anemia on morbidity, we determined factors associated with anemia after 96 weeks of antiretroviral therapy (ART) across age groups. An HIV-positive cohort (n=3,580) of children age 5-14, reproductive age adults 18-49, and older adults ≥50 from two randomized trials in Uganda and Zimbabwe were evaluated from initiation of therapy through 96 weeks. We conducted logistic and multinomial regression to evaluate common and differential determinants for anemia at 96 weeks on therapy. Prior to initiation of ART, the prevalence of anemia (age 5-11 <10.5 g/dl, 12-14 <11 g/dl, adult females <11 g/dl, adult males <12 g/dl) was 43%, which decreased to 13% at week 96 (p<0.001). Older adults had a significantly higher likelihood of anemia compared to reproductive age adults (OR 2.60, 95% CI 1.44-4.70, p=0.002). Reproductive age females had a significantly higher odds of anemia compared to men at week 96 (OR 2.56, 95% CI 1.92-3.40, p<0.001), and particularly a greater odds for microcytic anemia compared to males in the same age group (p=0.001). Other common factors associated with anemia included low body mass index (BMI) and microcytosis; greater increases in CD4 count to week 96 were protective. Thus, while ART significantly reduced the prevalence of anemia at 96 weeks, 13% of the population continued to be anemic. Specific groups, such as reproductive age females and older adults, have a greater odds of anemia and may guide clinicians to pursue further evaluation and management. |
| spellingShingle | Jaganath, D Walker, A Ssali, F Musiime, V Kiweewa, F Kityo, C Salata, R Mugyenyi, P HIV-associated anemia after 96 weeks on therapy: determinants across age ranges in Uganda and Zimbabwe. |
| title | HIV-associated anemia after 96 weeks on therapy: determinants across age ranges in Uganda and Zimbabwe. |
| title_full | HIV-associated anemia after 96 weeks on therapy: determinants across age ranges in Uganda and Zimbabwe. |
| title_fullStr | HIV-associated anemia after 96 weeks on therapy: determinants across age ranges in Uganda and Zimbabwe. |
| title_full_unstemmed | HIV-associated anemia after 96 weeks on therapy: determinants across age ranges in Uganda and Zimbabwe. |
| title_short | HIV-associated anemia after 96 weeks on therapy: determinants across age ranges in Uganda and Zimbabwe. |
| title_sort | hiv associated anemia after 96 weeks on therapy determinants across age ranges in uganda and zimbabwe |
| work_keys_str_mv | AT jaganathd hivassociatedanemiaafter96weeksontherapydeterminantsacrossagerangesinugandaandzimbabwe AT walkera hivassociatedanemiaafter96weeksontherapydeterminantsacrossagerangesinugandaandzimbabwe AT ssalif hivassociatedanemiaafter96weeksontherapydeterminantsacrossagerangesinugandaandzimbabwe AT musiimev hivassociatedanemiaafter96weeksontherapydeterminantsacrossagerangesinugandaandzimbabwe AT kiweewaf hivassociatedanemiaafter96weeksontherapydeterminantsacrossagerangesinugandaandzimbabwe AT kityoc hivassociatedanemiaafter96weeksontherapydeterminantsacrossagerangesinugandaandzimbabwe AT salatar hivassociatedanemiaafter96weeksontherapydeterminantsacrossagerangesinugandaandzimbabwe AT mugyenyip hivassociatedanemiaafter96weeksontherapydeterminantsacrossagerangesinugandaandzimbabwe |